Biogen and Eisai Discontinue Phase 3 ENGAGE AND EMERGE Trials of Ducanumab in AD

Mar 22, 2019 | Alzheimer, Challenging Results

Biogen and Eisai announced their joint decision to discontinue the global Phase 3 ENGAGE and EMERGE trials. They were designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. The decision to stop the trials is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. It was not based on safety concerns.


Pin It on Pinterest